Urotronic

Urotronic developed the Optilume family of paclitaxel-coated balloon catheters, a minimally invasive surgical therapy that combines mechanical dilation with localized delivery of paclitaxel. Clinical data from the PINNACLE trial showed a doubling in peak urinary flow rate at one year (+113%), with durable symptom improvement through four years in the EVEREST trial. The technology offers an alternative to traditional treatments by avoiding cutting, burning, steaming or permanent implants while preserving erectile and ejaculatory function. The first commercial procedure was completed in July 2023; FDA approvals were obtained for both urethral strictures and BPH catheter systems between December 2021–June 2023.